Plain-English translation of NCT07365930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study following 350 patients in Germany who have advanced liver cancer and are receiving atezolizumab plus bevacizumab as their first-line cancer treatment. Some patients will receive a special procedure called a transjugular intrahepatic portosystemic shunt (TIPS) before or alongside this medication, while others will receive the medication alone. The study will track how both groups do over time to see whether this procedure helps reduce liver complications and improves how well the treatment works.
Liver cancer often develops in people with cirrhosis, which causes dangerous pressure buildup in blood vessels around the liver. While this shunt procedure is known to help with that pressure, doctors aren't sure whether it also helps patients receiving this medication or whether it might interfere. This study will provide real-world evidence to help doctors decide who might benefit most from the procedure.
You likely qualify if…
You likely don't qualify if…
You will be enrolled in one of two groups depending on whether you receive the shunt procedure: one group will get the cancer medication alone, and the other will get the medication along with the shunt. The study will collect information about your treatment, any side effects, your quality of life, and how your liver function changes over time through regular clinical visits and check-ups. Your tissue samples may also be archived for future research. This is primarily an observational study, meaning researchers will track your existing treatment rather than assigning you to something new.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Roche Pharma AG, Heinrich-Heine University, Duesseldorf
Enrollment target
~350 participants
Started
December 2025
Primary completion
December 2031
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christoph Roderburg, Professor
Heinrich Heine University of Duesseldorf, University Hospital of Duesseldorf
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.